Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer

NCT01322802 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01322802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01322802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
March 6, 2012
Completion date
December 1, 2020
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii ovarian epithelial cancer, stage iii ovarian germ cell tumor, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor